|
|
|
| Overview |
| We are a London-based biopharmaceutical company
using our expertise in opioid antagonists to build a platform of
innovative solutions to common addictions and related disorders. We
hold patents covering the use of intranasal naloxone to treat Binge
Eating Disorder (“BED”) as well as patents covering addiction to
drugs including cocaine, amphetamine, and MDMA. We are currently
focused on advancing our treatment for BED, which has successfully
completed Phase II clinical trials, and a Phase II trial is planned
for the indication of Bulimia Nervosa. We are also applying our
technology to develop a treatment for managing the complications of
opioid drug addiction in collaboration with the National Institute
on Drug Abuse (NIDA), part of the National Institutes of Health.
|
|
